BRAF inhibitor:a novel therapy for ameloblastoma in mandible

摘要

Ameloblastoma is a benign but locally aggressive odontogenie neoplasm that accounts for 10% of all tumors arising in the mandible and maxilla (1).Eighty percent of ameloblastomas arise in the mandible,and they are usually found in young adults.It frequently recurs if not adequately resected.Therefore,the standard therapy for this tumor is complete bone resection with an adequate margin of safety: marginal or segmental osteotomy.However,aesthetic deformities,functional impairments and psychological impairments after radical surgery for large ameloblastoma, have been serious issues (1).